Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel
Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies....
Saved in:
Published in | Journal of experimental & clinical cancer research Vol. 36; no. 1; p. 178 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
08.12.2017
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies.
miR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth.
miR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3'-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo.
Silencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC. |
---|---|
AbstractList | Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies.
miR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth.
miR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3'-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo.
Silencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC. Abstract Background Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies. Methods miR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth. Results miR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3′-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo. Conclusions Silencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC. BACKGROUNDDocetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies.METHODSmiR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth.RESULTSmiR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3'-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo.CONCLUSIONSSilencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC. |
ArticleNumber | 178 |
Audience | Academic |
Author | Gu, Jun-Fei Zheng, Bin Li, Jing-Dong Chen, Jin-Suo Li, Wei Yang, Zhan Wang, Xiao-Lu Gao, Hai-Tao Zhang, Man-Li Liu, Kai-Long Qu, Chang-Bao Zhang, Yan-Ping Wen, Jin-Kun Zhang, Yong |
Author_xml | – sequence: 1 givenname: Zhan surname: Yang fullname: Yang, Zhan organization: Department of Science and Technology, The Second Hospital of Hebei Medical University, 215 Heping W Rd, Shijiazhuang, 050000, China – sequence: 2 givenname: Jin-Suo surname: Chen fullname: Chen, Jin-Suo organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 3 givenname: Jin-Kun surname: Wen fullname: Wen, Jin-Kun organization: Department of Biochemistry and Molecular Biology, Ministry of Education of China, Hebei Medical University, No. 361 Zhongshan E Rd, Shijiazhuang, 050017, China – sequence: 4 givenname: Hai-Tao surname: Gao fullname: Gao, Hai-Tao organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 5 givenname: Bin surname: Zheng fullname: Zheng, Bin organization: Department of Biochemistry and Molecular Biology, Ministry of Education of China, Hebei Medical University, No. 361 Zhongshan E Rd, Shijiazhuang, 050017, China – sequence: 6 givenname: Chang-Bao surname: Qu fullname: Qu, Chang-Bao organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 7 givenname: Kai-Long surname: Liu fullname: Liu, Kai-Long organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 8 givenname: Man-Li surname: Zhang fullname: Zhang, Man-Li organization: Department of Emergency Medicine, The second hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China – sequence: 9 givenname: Jun-Fei surname: Gu fullname: Gu, Jun-Fei organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 10 givenname: Jing-Dong surname: Li fullname: Li, Jing-Dong organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 11 givenname: Yan-Ping surname: Zhang fullname: Zhang, Yan-Ping organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 12 givenname: Wei surname: Li fullname: Li, Wei organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 13 givenname: Xiao-Lu surname: Wang fullname: Wang, Xiao-Lu organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China – sequence: 14 givenname: Yong surname: Zhang fullname: Zhang, Yong email: zhangyong89@sina.com organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China. zhangyong89@sina.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29216925$$D View this record in MEDLINE/PubMed |
BookMark | eNptkttq3DAQhk1JaA7tA_SmGAqlN0411sm6KYTQQyBQ6OGyCK082lWwpa2lDc3bV66TsAtFFxKab37m8J9VRyEGrKpXQC4AOvE-ASVMNARkQwRTDX1WnYLkolFKiKO990l1ltItIQIUqOfVSataEKrlp9Wv737AYH1Y19HVo__WgKKm4dvaBzuhSZjqvMHabnCMCUPy2d_5fD_T2ymmbHIJmmBxqi0OQ6Fj3UeL2fzB4UV17MyQ8OXDfV79_PTxx9WX5ubr5-ury5vGilblRkk0QDklyoK0qgfCemWplJJJJCvqROes6Cn2LVrXcQKKM4W8M9w5rig9r64X3T6aW72d_Gimex2N1_8-4rTWZsreDqjdyrWKGVwBMEaYXXFqiORlHsBch33R-rBobXerEXuLIU9mOBA9jAS_0et4p7mcReZi3j0ITPH3DlPWo0_zbEzAuEsalCwdcNVBQd8s6NqU0nxwsSjaGdeXnAkqqRCqUBf_ocrpcfS2WMKVHR4mvN1L2KAZ8ibFYZd9DOkQhAW0ZZVpQvfUJhA9W0wvFtPFYnq2mJ7be70_n6eMR0_Rv768zFw |
CitedBy_id | crossref_primary_10_1096_fj_201900537R crossref_primary_10_1097_MD_0000000000034998 crossref_primary_10_1111_joa_13612 crossref_primary_10_1186_s12964_018_0270_x crossref_primary_10_1080_21655979_2022_2068756 crossref_primary_10_1111_iju_15043 crossref_primary_10_1016_j_ncrna_2022_02_002 crossref_primary_10_1186_s12935_020_1098_1 crossref_primary_10_3390_ijms21020404 crossref_primary_10_1177_15353702231191199 crossref_primary_10_1158_1535_7163_MCT_19_0051 crossref_primary_10_3389_fcell_2021_737812 crossref_primary_10_1038_s41598_023_45250_9 crossref_primary_10_1111_jcmm_16202 crossref_primary_10_1038_s41374_022_00736_4 crossref_primary_10_18632_aging_202271 crossref_primary_10_3390_foods13060960 crossref_primary_10_3390_genes12081206 crossref_primary_10_3389_fonc_2021_710525 crossref_primary_10_3390_biom13020266 crossref_primary_10_3390_ijms21176183 crossref_primary_10_1111_acel_13430 crossref_primary_10_3390_cancers13030550 crossref_primary_10_1186_s12935_022_02475_4 crossref_primary_10_1002_cam4_3726 crossref_primary_10_1186_s13046_020_01814_5 crossref_primary_10_7717_peerj_7451 crossref_primary_10_1111_febs_16681 crossref_primary_10_1002_jcb_27906 crossref_primary_10_3892_mmr_2022_12878 crossref_primary_10_1186_s12935_021_02020_9 crossref_primary_10_1186_s13072_023_00483_w crossref_primary_10_1042_BSR20190150 crossref_primary_10_1096_fj_202300980R crossref_primary_10_1007_s10555_024_10168_9 crossref_primary_10_1038_s41388_018_0602_8 crossref_primary_10_1134_S0006297922050030 crossref_primary_10_1186_s43556_020_00004_1 crossref_primary_10_1002_jcb_29374 crossref_primary_10_1002_jcb_29451 crossref_primary_10_2174_1871520622666220601093452 crossref_primary_10_3389_fimmu_2023_1135753 crossref_primary_10_1080_15384047_2019_1599659 crossref_primary_10_2176_jns_nmc_2023_0200 crossref_primary_10_1007_s11033_022_07763_w crossref_primary_10_1002_jcp_29724 crossref_primary_10_1038_s41419_021_03854_x crossref_primary_10_3390_antiox12061217 crossref_primary_10_1016_j_intimp_2020_107355 crossref_primary_10_1111_andr_13086 crossref_primary_10_1016_j_reprotox_2022_04_003 crossref_primary_10_1186_s40709_021_00151_8 crossref_primary_10_3390_cimb45050273 crossref_primary_10_2147_COPD_S298465 crossref_primary_10_3892_mmr_2021_12221 crossref_primary_10_1038_s41419_019_1943_0 crossref_primary_10_3389_fonc_2019_01535 crossref_primary_10_3390_antiox10050789 crossref_primary_10_2147_CMAR_S232757 crossref_primary_10_2174_1874609816666230816152744 crossref_primary_10_1016_j_bbcan_2020_188481 crossref_primary_10_1016_j_redox_2018_04_020 crossref_primary_10_3390_molecules24122335 crossref_primary_10_3389_fonc_2020_00850 crossref_primary_10_1096_fj_202200673RRR crossref_primary_10_1038_s12276_021_00623_w |
Cites_doi | 10.1038/onc.2012.360 10.1016/j.cell.2004.12.035 10.1002/path.2855 10.1111/j.1442-2042.2009.02341.x 10.2174/138161208784246225 10.1016/j.biocel.2006.03.013 10.1016/j.bbrc.2004.01.118 10.1158/0008-5472.CAN-16-2355 10.18632/oncotarget.12684 10.1172/JCI82884 10.1016/j.yexcr.2016.03.001 10.1038/sj.onc.1209632 10.1097/00001622-200011000-00006 10.1074/jbc.M707773200 10.1158/1078-0432.CCR-06-0147 10.1158/0008-5472.CAN-14-0795 10.1038/onc.2013.574 10.1016/j.bcp.2013.12.009 10.1158/0008-5472.CAN-09-0419 10.1016/j.ajpath.2012.08.011 10.1186/1471-2407-14-308 10.1152/physrev.00011.2005 10.1093/emboj/20.11.2835 10.1016/j.freeradbiomed.2011.09.014 10.1186/gb-2010-11-8-r90 10.1097/CEJ.0b013e32834a7f0c 10.7150/jca.15620 10.1158/1535-7163.MCT-06-0272 10.1038/aps.2010.48 10.1158/0008-5472.CAN-10-1447 10.1038/sj.bjc.6604081 10.1016/j.molonc.2013.10.001 10.1080/01635581.2014.868909 10.18632/oncotarget.10950 10.1006/bbrc.1997.6943 10.1111/j.1365-2559.2006.02412.x 10.1002/pros.20824 10.1016/S0929-6646(08)60100-X 10.18632/oncotarget.8624 10.1074/jbc.M203929200 10.7150/jca.6394 10.1038/sj.onc.1203716 10.1016/j.eururo.2016.05.002 10.1517/14796694.1.1.91 10.1186/1476-4598-13-234 10.1182/blood-2005-12-040972 10.1186/1471-2407-11-221 10.1038/nm.3247 10.1002/jcb.20794 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2017 BioMed Central Ltd. The Author(s). 2017 |
Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: The Author(s). 2017 |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1186/s13046-017-0649-3 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 178 |
ExternalDocumentID | oai_doaj_org_article_fbf294aeb114404cb53a07521614f8ed A546373669 10_1186_s13046_017_0649_3 29216925 |
Genre | Journal Article |
GrantInformation_xml | – fundername: The National Natural Science Foundation of China grantid: 81672555 – fundername: The National Natural Science Foundation of China grantid: 81600237 – fundername: ; grantid: 81672555; 81600237 |
GroupedDBID | --- -5E -5G -A0 -BR 0R~ 29K 2WC 3V. 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ ABDBF ABUWG ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CS3 D-I DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M AAYXX CITATION AFGXO ABVAZ AFNRJ 7X8 5PM |
ID | FETCH-LOGICAL-c629t-97ea135309c17c9d104d9c377747e0b3f68fc6d3ed2ecf85019549e58a5ff5933 |
IEDL.DBID | RPM |
ISSN | 1756-9966 0392-9078 |
IngestDate | Tue Oct 22 15:12:18 EDT 2024 Tue Sep 17 21:15:21 EDT 2024 Fri Oct 25 06:50:08 EDT 2024 Thu Feb 22 23:30:41 EST 2024 Tue Nov 12 22:53:44 EST 2024 Tue Aug 20 22:12:35 EDT 2024 Fri Sep 13 05:35:14 EDT 2024 Wed Oct 16 01:00:27 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Bach2 HO-1 miR-193a-5p Prostate cancer Chemoresistance Docetaxel |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c629t-97ea135309c17c9d104d9c377747e0b3f68fc6d3ed2ecf85019549e58a5ff5933 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721613/ |
PMID | 29216925 |
PQID | 1975015981 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_fbf294aeb114404cb53a07521614f8ed pubmedcentral_primary_oai_pubmedcentral_nih_gov_5721613 proquest_miscellaneous_1975015981 gale_infotracmisc_A546373669 gale_infotracacademiconefile_A546373669 gale_healthsolutions_A546373669 crossref_primary_10_1186_s13046_017_0649_3 pubmed_primary_29216925 |
PublicationCentury | 2000 |
PublicationDate | 2017-12-08 |
PublicationDateYYYYMMDD | 2017-12-08 |
PublicationDate_xml | – month: 12 year: 2017 text: 2017-12-08 day: 08 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of experimental & clinical cancer research |
PublicationTitleAlternate | J Exp Clin Cancer Res |
PublicationYear | 2017 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | E Francini (649_CR5) 2016; 70 M Pennati (649_CR11) 2014; 87 J Busserolles (649_CR45) 2006; 38 KH Pulkkinen (649_CR35) 2011; 51 J Zhou (649_CR15) 2016; 7 XB Shi (649_CR10) 2015; 75 JM Grad (649_CR49) 2000; 12 S Reagan-Shaw (649_CR51) 2008; 68 YB Wetherill (649_CR1) 2006; 5 MA Alaoui-Jamali (649_CR44) 2009; 69 A Matsumoto (649_CR4) 2009; 16 T Kirkegaard (649_CR32) 2006; 48 P Sacca (649_CR47) 2007; 97 S Zhang (649_CR24) 2014; 66 R Roychoudhuri (649_CR52) 2016; 126 SG Patterson (649_CR37) 2006; 25 R Sullivan (649_CR20) 2008; 14 M Puhr (649_CR6) 2012; 181 IE Eder (649_CR3) 2005; 1 S Rajput (649_CR43) 2012; 21 BA Walter (649_CR33) 2013; 4 Z Yang (649_CR28) 1852; 2015 S Sasaki (649_CR36) 2000; 19 SS Lee (649_CR46) 2008; 107 GH Shi (649_CR12) 2010; 31 C Yoshida (649_CR25) 2007; 109 G Ploussard (649_CR39) 2010; 70 K Ogawa (649_CR22) 2001; 20 E Chun (649_CR48) 2004; 315 T Kietzmann (649_CR23) 2003; 278 S Swaminathan (649_CR26) 2013; 19 Y Yang (649_CR13) 2013; 32 Y Li (649_CR19) 2011; 224 SW Ryter (649_CR18) 2006; 86 C Huang (649_CR42) 2016; 7 H Deng (649_CR17) 2014; 13 T Yoshino (649_CR50) 2006; 12 SM Dehm (649_CR2) 2006; 99 QF Ye (649_CR7) 2012; 3 Y Xie (649_CR38) 2008; 283 BP Lewis (649_CR30) 2005; 120 JY Seo (649_CR29) 2017; 2017 L Heinemann (649_CR34) 2011; 11 C Jacques (649_CR16) 2016; 7 Q Cao (649_CR40) 2016; 7 D Wen (649_CR9) 2017; 77 SK Leivonen (649_CR41) 2014; 8 CJ Nie (649_CR8) 2016; 342 K Itoh (649_CR21) 1997; 236 T Yu (649_CR14) 2015; 34 X Wang (649_CR27) 2014; 14 D Betel (649_CR31) 2010; 11 |
References_xml | – volume: 32 start-page: 3432 year: 2013 ident: 649_CR13 publication-title: Oncogene doi: 10.1038/onc.2012.360 contributor: fullname: Y Yang – volume: 120 start-page: 15 year: 2005 ident: 649_CR30 publication-title: Cell doi: 10.1016/j.cell.2004.12.035 contributor: fullname: BP Lewis – volume: 224 start-page: 90 year: 2011 ident: 649_CR19 publication-title: J Pathol doi: 10.1002/path.2855 contributor: fullname: Y Li – volume: 16 start-page: 687 year: 2009 ident: 649_CR4 publication-title: Int J Urol doi: 10.1111/j.1442-2042.2009.02341.x contributor: fullname: A Matsumoto – volume: 3 start-page: 879 year: 2012 ident: 649_CR7 publication-title: Oncol Lett contributor: fullname: QF Ye – volume: 14 start-page: 1113 year: 2008 ident: 649_CR20 publication-title: Curr Pharm Des doi: 10.2174/138161208784246225 contributor: fullname: R Sullivan – volume: 38 start-page: 1510 year: 2006 ident: 649_CR45 publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2006.03.013 contributor: fullname: J Busserolles – volume: 315 start-page: 771 year: 2004 ident: 649_CR48 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2004.01.118 contributor: fullname: E Chun – volume: 77 start-page: 3244 year: 2017 ident: 649_CR9 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-2355 contributor: fullname: D Wen – volume: 7 start-page: 77468 year: 2016 ident: 649_CR40 publication-title: Oncotarget doi: 10.18632/oncotarget.12684 contributor: fullname: Q Cao – volume: 126 start-page: 599 year: 2016 ident: 649_CR52 publication-title: J Clin Invest doi: 10.1172/JCI82884 contributor: fullname: R Roychoudhuri – volume: 342 start-page: 20 year: 2016 ident: 649_CR8 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2016.03.001 contributor: fullname: CJ Nie – volume: 25 start-page: 6113 year: 2006 ident: 649_CR37 publication-title: Oncogene doi: 10.1038/sj.onc.1209632 contributor: fullname: SG Patterson – volume: 12 start-page: 543 year: 2000 ident: 649_CR49 publication-title: Curr Opin Oncol doi: 10.1097/00001622-200011000-00006 contributor: fullname: JM Grad – volume: 2015 start-page: 1477 year: 1852 ident: 649_CR28 publication-title: Biochim Biophys Acta contributor: fullname: Z Yang – volume: 283 start-page: 3349 year: 2008 ident: 649_CR38 publication-title: J Biol Chem doi: 10.1074/jbc.M707773200 contributor: fullname: Y Xie – volume: 12 start-page: 6116 year: 2006 ident: 649_CR50 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-0147 contributor: fullname: T Yoshino – volume: 2017 start-page: 5906189 year: 2017 ident: 649_CR29 publication-title: Mediat Inflamm contributor: fullname: JY Seo – volume: 75 start-page: 5309 year: 2015 ident: 649_CR10 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-0795 contributor: fullname: XB Shi – volume: 34 start-page: 413 year: 2015 ident: 649_CR14 publication-title: Oncogene doi: 10.1038/onc.2013.574 contributor: fullname: T Yu – volume: 87 start-page: 579 year: 2014 ident: 649_CR11 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2013.12.009 contributor: fullname: M Pennati – volume: 69 start-page: 8017 year: 2009 ident: 649_CR44 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-0419 contributor: fullname: MA Alaoui-Jamali – volume: 181 start-page: 2188 year: 2012 ident: 649_CR6 publication-title: Am J Pathol doi: 10.1016/j.ajpath.2012.08.011 contributor: fullname: M Puhr – volume: 14 start-page: 308 year: 2014 ident: 649_CR27 publication-title: BMC Cancer doi: 10.1186/1471-2407-14-308 contributor: fullname: X Wang – volume: 86 start-page: 583 year: 2006 ident: 649_CR18 publication-title: Physiol Rev doi: 10.1152/physrev.00011.2005 contributor: fullname: SW Ryter – volume: 20 start-page: 2835 year: 2001 ident: 649_CR22 publication-title: EMBO J doi: 10.1093/emboj/20.11.2835 contributor: fullname: K Ogawa – volume: 51 start-page: 2124 year: 2011 ident: 649_CR35 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2011.09.014 contributor: fullname: KH Pulkkinen – volume: 11 start-page: R90 year: 2010 ident: 649_CR31 publication-title: Genome Biol doi: 10.1186/gb-2010-11-8-r90 contributor: fullname: D Betel – volume: 21 start-page: 205 year: 2012 ident: 649_CR43 publication-title: Eur J Cancer Prev doi: 10.1097/CEJ.0b013e32834a7f0c contributor: fullname: S Rajput – volume: 7 start-page: 1740 year: 2016 ident: 649_CR15 publication-title: J Cancer doi: 10.7150/jca.15620 contributor: fullname: J Zhou – volume: 5 start-page: 3181 year: 2006 ident: 649_CR1 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-06-0272 contributor: fullname: YB Wetherill – volume: 31 start-page: 867 year: 2010 ident: 649_CR12 publication-title: Acta Pharmacol Sin doi: 10.1038/aps.2010.48 contributor: fullname: GH Shi – volume: 70 start-page: 9253 year: 2010 ident: 649_CR39 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-1447 contributor: fullname: G Ploussard – volume: 97 start-page: 1683 year: 2007 ident: 649_CR47 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604081 contributor: fullname: P Sacca – volume: 8 start-page: 93 year: 2014 ident: 649_CR41 publication-title: Mol Oncol doi: 10.1016/j.molonc.2013.10.001 contributor: fullname: SK Leivonen – volume: 66 start-page: 315 year: 2014 ident: 649_CR24 publication-title: Nutr Cancer doi: 10.1080/01635581.2014.868909 contributor: fullname: S Zhang – volume: 7 start-page: 54503 year: 2016 ident: 649_CR16 publication-title: Oncotarget doi: 10.18632/oncotarget.10950 contributor: fullname: C Jacques – volume: 236 start-page: 313 year: 1997 ident: 649_CR21 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1997.6943 contributor: fullname: K Itoh – volume: 48 start-page: 787 year: 2006 ident: 649_CR32 publication-title: Histopathology doi: 10.1111/j.1365-2559.2006.02412.x contributor: fullname: T Kirkegaard – volume: 68 start-page: 1624 year: 2008 ident: 649_CR51 publication-title: Prostate doi: 10.1002/pros.20824 contributor: fullname: S Reagan-Shaw – volume: 107 start-page: 355 year: 2008 ident: 649_CR46 publication-title: J Formos Med Assoc doi: 10.1016/S0929-6646(08)60100-X contributor: fullname: SS Lee – volume: 7 start-page: 35874 year: 2016 ident: 649_CR42 publication-title: Oncotarget doi: 10.18632/oncotarget.8624 contributor: fullname: C Huang – volume: 278 start-page: 17927 year: 2003 ident: 649_CR23 publication-title: J Biol Chem doi: 10.1074/jbc.M203929200 contributor: fullname: T Kietzmann – volume: 4 start-page: 350 year: 2013 ident: 649_CR33 publication-title: J Cancer doi: 10.7150/jca.6394 contributor: fullname: BA Walter – volume: 19 start-page: 3739 year: 2000 ident: 649_CR36 publication-title: Oncogene doi: 10.1038/sj.onc.1203716 contributor: fullname: S Sasaki – volume: 70 start-page: 410 year: 2016 ident: 649_CR5 publication-title: Eur Urol doi: 10.1016/j.eururo.2016.05.002 contributor: fullname: E Francini – volume: 1 start-page: 93 year: 2005 ident: 649_CR3 publication-title: Future Oncol doi: 10.1517/14796694.1.1.91 contributor: fullname: IE Eder – volume: 13 start-page: 234 year: 2014 ident: 649_CR17 publication-title: Mol Cancer doi: 10.1186/1476-4598-13-234 contributor: fullname: H Deng – volume: 109 start-page: 1211 year: 2007 ident: 649_CR25 publication-title: Blood doi: 10.1182/blood-2005-12-040972 contributor: fullname: C Yoshida – volume: 11 start-page: 221 year: 2011 ident: 649_CR34 publication-title: BMC Cancer doi: 10.1186/1471-2407-11-221 contributor: fullname: L Heinemann – volume: 19 start-page: 1014 year: 2013 ident: 649_CR26 publication-title: Nat Med doi: 10.1038/nm.3247 contributor: fullname: S Swaminathan – volume: 99 start-page: 333 year: 2006 ident: 649_CR2 publication-title: J Cell Biochem doi: 10.1002/jcb.20794 contributor: fullname: SM Dehm |
SSID | ssj0061919 |
Score | 2.4868321 |
Snippet | Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to... BACKGROUNDDocetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to... Abstract Background Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC)... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 178 |
SubjectTerms | Apoptosis Bach2 Cancer Chemoresistance Chemotherapy Docetaxel Genes HO-1 miR-193a-5p Prostate cancer RNA |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_Sg3gRtX5MrTWCIAihm8nk4x1rsZRCPaiFXiRkMgku2Jmls4X--X1vZnbZwYMXr5s3kLzPX_Z9hLGP1gUAq7WoFQRRmbwQtSylyFChPtmAfpMahS-_mfOr6uJaX-889UU1YeN44JFxx7nOJVQBXQqlIatYaxUwzJWIVKrsUjN43wVsLlOjD8ZbgYQphymdOe4lJQAFeWQMwSDULAoNw_r_dsk7MWleL7kTgM6esacTcuQn446fs0epfcEeX0658X3268eSGogwFPEu85vld4GoKQi94suWoGGfeo5oj6OUbrqe6tbHhyOIekW9H4g6eSQluOX0dz5Sd7zB8LYO9-nPS3Z19vXn6bmYHk8Q0ZSwFmBToDctFhCljdDgtauBqCzCPZsWtcrG5WgalZoyxew0NQ5WkLQLOmcNSr1ie23XpjeMR4MfJCNTRCyQkoVE-USao4jRX2Uo2OcNM_1qnJHhh7uFM37kvEfOe-K8VwX7QuzeEtJ46-EHFLqfhO7_JfSCvSdh-bFXdGuk_oSG-1tlDO7p00BBZooyi2HqNsAT0cCrGeXhjBLNK86WP2wUwtMS1aS1qbvrvUQdRzAFThbs9agg21OVgHuFUhfMzlRnduz5Srv8PUz31jROSaqD_8Gnt-xJSUpP5TfukO2tb-_SOwRR6_posJcHciAXVg priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3di9QwEA_nCeKL-G311AiCIEQ3TZN0HkRO8TiE80FduBcJaZrowl27bvfg_O-dabvLFs_XZro0mZnMb3a-GHtpSw9gtRaVAi8Kk2aikrkUCQqUJ-vx3qRC4ZMv5nhefD7Vp3tsM95qPMDuSteO5knNV2dvLn__eY8K_65X-NK87SSF9wTdt2hgQahr7HpeoKNOmXzFNqiAroKEMbB55WvUGBhyaYDmZu9Yqb6Z_79X9o7NmuZT7hioo9vs1ogs-eEgCnfYXmzushsnY-z8HvvxbUEFRmiqeJv4-eKrQFTlhV7yRUPQsYsdRzTIkYvnbUd57cNgCaJeUm0IolIeSEhWnP7uR-qW12j-1v4ynt1n86NP3z8ei3G4gggmh7UAGz3NvJhBkDZAjW5ZDUFZhIM2ziqVTJmCqVWs8xhSqamwsICoS69T0qDUA7bftE18xHgw-EI0MgbECjFaiBRvpD6LiA5Ugoy93hymWw49NFzve5TGDUxwyARHTHAqYx_ouLeE1P66f9CufrpRm1yqUg6FRztDsekiVFp5xD7IO1mkMtYZe07MckMt6VaJ3SE1_7fKGPymVz0FCRbyLPixGgF3RA2xJpQHE0pUvzBZfrERCEdLlLPWxPaicxJ1AMEWlDJjDwcB2e5qI2cZsxPRmWx7utIsfvXdvzW1W5Lq8X9_8wm7mZNQU85NecD216uL-BSR07p61uvDXyYdEa4 priority: 102 providerName: Scholars Portal |
Title | Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29216925 https://search.proquest.com/docview/1975015981 https://pubmed.ncbi.nlm.nih.gov/PMC5721613 https://doaj.org/article/fbf294aeb114404cb53a07521614f8ed |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZtB2MvY_d56zINBoOBmtiybo9NaSmDlJKtEAZD2LLUBRo7xCn05_ccX0LM3vbiB-vYWD6fdD5J50LIV6UzY5QQLOcmY6kME5bHScyCSQFPKoN5EwOFZ1fy8ib9sRCLAyL6WJjGad_ly5PybnVSLv82vpXrlRv3fmLj69mZwIwzMR8fkkN4Yb9Eb6dfWBA01TwmYPgZrPx0d5QZazmuYzwHZDgxgyU2DIvoJAbeZbBS9p5datL3_ztJ71mpoQflnkm6eEGed1ySnrbf_JIc-PIVeTrrTstfkz8_lxhSBMaJVoGulnMGPCpjYk2XJZLF2tcU-B8Fva2qGj3Z21ISKL3GaBDgodQhLDYUN_hBuqIFGLxt9uDv3pCbi_NfZ5esK6fAnEzMlhnlM6xyMTEuVs4UsBArjOMKCKDyk5wHqYOTBfdF4l3QAkMJU-OFzkQIwnD-lhyVVenfE-okPOBl7B2wA--V8XjCiJkVgQ_wYCLyvf-Zdt1mzbDNakNL2yrBghIsKsHyiEzxd-8EMeF1c6Pa3NpO7TbkITFpBpYFT6NTlwueAdtBHKRB-yIin1FZto0e3Q1be4rp_hWXEr7pWyOBAxd05rIu_gB6hCmwBpLHA0kYcG7Q_KUHhMUm9FIrfXVf2xhQD_TK6Dgi71qA7HrV4ywiagCdQbeHLQD_Jt93B_cP__3kR_IsQdCjF44-Jkfbzb3_BFxqm49gBC3UiDyZnl9dz0fNjgRcZ6mG63z6e9SMrUcx3x8G |
link.rule.ids | 230,315,730,783,787,867,888,2109,24330,27936,27937,31732,33757,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_nCeqL-HlWTy-CIAi5bZsmaR7Pw2PV20P0Du5FQpomWrhtl-0e-Oc7049li2--NtPSdGYyv-l8EfJO5VZrJQQruLYskyFmRZImLOgM5ElZODexUHhxIedX2Zdrcb1HxFgL0yXtu6I6rm-Wx3X1u8utXC3dbMwTm31bnArsOJPw2R1yF_Q1zkYnvT-AwSXo5nnEYPoZ-H75EMxMcjlrE4wEMjyawRZrhmN0Ug1P0zgre8cydQ38_z2md-zUNIdyxyidPSIPBzRJT_q3fkz2fP2E3FsM8fKn5OePCouKwDzRJtBl9Z0BkrJMrGhVI1xsfUsBAVLg3LJpMZe9HyaB1CusBwEkSh0KxpriL36gbmgJJm9j__ibZ-Tq7NPl6ZwNAxWYk6neMK28xTkXsXaJcroEV6zUjiuAgMrHBQ8yD06W3JepdyEXWEyYaS9yK0IQmvPnZL9uav-CUCfhBi8T7wAfeK-0xxgj9lYERMCDjsiH8WOaVd83w3T-Ri5NzwQDTDDIBMMj8hE_95YQW153F5r1LzMw3oQipDqzYFswHp25QnALeAclIQu5LyNyhMwyff3oVnHNCTb8V1xKeKf3HQWqLvDM2aECAXaETbAmlIcTSlA5N1l-OwqEwSXMU6t9c9uaBOQeAJbOk4gc9AKy3dUoZxFRE9GZbHu6AgrQdfweBP7lf995RO7PLxfn5vzzxddX5EGKCoA5Ofkh2d-sb_1rQFab4k2nR38BoSYc_Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEBZtCqEvpXedpI0KhUJB8SFblh7TtEt6bAhtA3kpQpal1pC1zXoD_fmd8bGs6VtfrbGxPDOabzwXIW9yaZTKs4wVXBmWCh-xIk5i5lUK8pQbODexUHh5Ic6v0s_X2fXOqK8-ad8W1Ul9szqpq999bmW7suGUJxZeLs8y7DgT87AtfXiX3AOdjcTkqA-HMLgF_UyPCMw_A_9PjgHNWIqwizEayPB4BnusGI7SSRQ8UeG87B3r1Dfx__eo3rFV8zzKHcO0eEgejIiSng5v_ojccfVjsr8cY-ZPyM_vFRYWgYmijaer6hsDNGVY1tKqRsjYuY4CCqTAvVXTYT77MFACqVusCQE0Si0Kx5rib36gbmgJZm9j_ribp-Rq8fHH2TkbhyowKxK1YSp3BmddRMrGuVUluGOlsjwHGJi7qOBeSG9FyV2ZOOtlhgWFqXKZNJn3meL8Gdmrm9q9INQKuMGJ2FnACM7lymGcEfsrAirgXgXk3fQxdTv0ztC9zyGFHpiggQkamaB5QN7j594SYtvr_kKz_qVH5mtf-ESlBuwLxqRTW2TcAOZBaUi9dGVAjpFZeqgh3SqvPsWm_zkXAt7pbU-B6gs8s2asQoAdYSOsGeXRjBLUzs6WX08CoXEJc9Vq19x2OgbZB5ClZByQ54OAbHc1yVlA8pnozLY9XwEl6Lt-j0J_8N93HpP9yw8L_fXTxZdDcj9B-ce0HHlE9jbrW_cSwNWmeNWr0V_CTR4Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Silencing+of+miR-193a-5p+increases+the+chemosensitivity+of+prostate+cancer+cells+to+docetaxel&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Yang%2C+Zhan&rft.au=Chen%2C+Jin-Suo&rft.au=Wen%2C+Jin-Kun&rft.au=Gao%2C+Hai-Tao&rft.date=2017-12-08&rft.eissn=1756-9966&rft.volume=36&rft.issue=1&rft.spage=178&rft_id=info:doi/10.1186%2Fs13046-017-0649-3&rft_id=info%3Apmid%2F29216925&rft.externalDocID=29216925 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |